Bharat Biotech International Limited
Bharat Biotech is a pioneering biotechnology company focused on innovative vaccine development and manufacturing. Their mission is to deliver affordable, safe, and high-quality vaccines and bio-therapeutics to help people prevail over diseases, with a focus on emerging markets. They are committed to leading innovation in biotechnology and have a rich history of research, development, and global collaborations.
Industries
Nr. of Employees
large (251-1000)
Bharat Biotech International Limited
Genome Valley Shameerpet Hyderabad – 500 078 Telangana INDIA
Patents
Process for enterovirus purification and inactivation and vaccine compositions obtained thereof
US-11911457-B2
View Details
Process for enterovirus purification and inactivation and vaccine compositions obtained thereof
US-11911457-B2
View DetailsProducts
Inactivated whole-virion COVID-19 vaccine (2-dose, refrigerated)
Inactivated whole-virion vaccine produced in high-containment facilities, formulated with adjuvant and supplied as a refrigerated liquid presentation for a two-dose primary series.
Oral rotavirus vaccine (oral liquid formulation)
Oral rotavirus vaccine delivered as a single-dose liquid presentation suitable for mass immunization campaigns.
Rabies vaccine (inactivated/parenteral relaunch)
Parenteral rabies vaccine product reintroduced for supply to immunization programs and healthcare providers to address local shortages.
Typhoid conjugate vaccine (conjugate presentation)
Conjugate vaccine combining capsular polysaccharide antigens with carrier protein to elicit T-cell dependent immune responses suitable for infants and older age groups; deployed following international regulatory engagement.
Inactivated whole-virion COVID-19 vaccine (2-dose, refrigerated)
Inactivated whole-virion vaccine produced in high-containment facilities, formulated with adjuvant and supplied as a refrigerated liquid presentation for a two-dose primary series.
Oral rotavirus vaccine (oral liquid formulation)
Oral rotavirus vaccine delivered as a single-dose liquid presentation suitable for mass immunization campaigns.
Rabies vaccine (inactivated/parenteral relaunch)
Parenteral rabies vaccine product reintroduced for supply to immunization programs and healthcare providers to address local shortages.
Typhoid conjugate vaccine (conjugate presentation)
Conjugate vaccine combining capsular polysaccharide antigens with carrier protein to elicit T-cell dependent immune responses suitable for infants and older age groups; deployed following international regulatory engagement.
Services
Support for international product registration, market authorization activities, partnerships for market access, and management of global supply of vaccines and biologics.
End-to-end clinical trial services including protocol development, multi-phase trial conduct, site monitoring, and ethical oversight.
Manufacturing services using high-containment facilities and cell-culture platforms, including formulation, fill–finish (including pre-filled syringes) and packaging for global distribution.
Support for collaborative R&D agreements, licensing arrangements, and transfer of manufacturing technology to partners and contract manufacturers.
Support for international product registration, market authorization activities, partnerships for market access, and management of global supply of vaccines and biologics.
End-to-end clinical trial services including protocol development, multi-phase trial conduct, site monitoring, and ethical oversight.
Manufacturing services using high-containment facilities and cell-culture platforms, including formulation, fill–finish (including pre-filled syringes) and packaging for global distribution.
Support for collaborative R&D agreements, licensing arrangements, and transfer of manufacturing technology to partners and contract manufacturers.
Expertise Areas
- Vaccine development and manufacturing
- Clinical trial management and human challenge trials
- Cell-culture and inactivated vaccine platforms
- Recombinant protein and conjugate vaccine R&D
Key Technologies
- BSL-3 containment facilities
- Whole-virion inactivated vaccine platform
- Mammalian cell culture production (Vero, MDCK)
- Recombinant protein expression
News & Updates
INSA India fellowship for 2025
Awarded to Dr. Krishna Ella, co-founder of Bharat Biotech, for contributions to vaccine technology and biotechnology.
Bharat Biotech recognised as one of the top 20 innovative companies at the CII Summit - 2024
Best Production/Process Development Award at the 16th annual Vaccine Industry Excellence (ViE) Awards - 2023
INSA India fellowship for 2025
Awarded to Dr. Krishna Ella, co-founder of Bharat Biotech, for contributions to vaccine technology and biotechnology.